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ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE
CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE
(CES-D)
Meads DM, McKenna SP, Doward LC
Galen Research, Manchester, UK
OBJECTIVES: The Centre for Epidemiologic Studies Depression
Scale (CES-D) is one of the most widely used depression ques-
tionnaires; it has been translated into many languages and is fre-
quently used in multi-national studies. This research sought to
examine whether different language versions of the CES-D were
affected by country (cultural)-related differential item func-
tioning (DIF). METHODS: CES-D data were available from
depressed patients in the UK (n = 177), US (n = 100), Germany
(n = 78) and France (n = 124). The data were pooled and applied
to the one-parameter Rasch item-response model for analysis
and to identify cross-cultural DIF. RESULTS: The UK and
German CES-D did not ﬁt the Rasch model (Chi2 p < 0.001) sug-
gesting that summation of item scores in these countries is not
justiﬁed. Four items in the UK (including 2 of the 4 positively
worded items) and 2 items in Germany misﬁtted. The US CES-
D exhibited borderline overall misﬁt to the Rasch model (Chi2
p < 0.01) with no item misﬁt and the French data ﬁtted the Rasch
model (with 1 item misﬁtting). The pooled data from the 4 coun-
tries did not ﬁt the Rasch model (Chi2 p < 0.001) and DIF was
observed in 7 items (including all of the positively worded items).
DIF between the US and UK (5 items), the US and Germany 
(5 items) and US and France (4 items) was greater than that
between UK and Germany (1 item), the UK and France (2 items)
and Germany and France (3 items). CONCLUSIONS: CES-D
data from these countries cannot be pooled justiﬁably without
ﬁrst accounting for DIF by culture. DIF appeared to be greater
between the US and Europe than within European countries. In
addition, the use of both positively and negatively worded items
in a questionnaire may introduce bias.
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MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE
ABUSE TREATMENT: A PROPORTIONAL HAZARD APPROACH
Ciesla JR,Valle M, Spear SF
Northern Illinois University, DeKalb, IL, USA
OBJECTIVES: Cox regression is used to analyze relapse patterns
of adolescents treated for psychoactive substance use disorder
(PSUD). The objective is to evaluate the role numerous psy-
chosocial, treatment and environmental characteristics play in
the relapse process in this treatment population. It is clear that
the PSUD disease and recovery process are unique in adolescents
and that relapse and recovery need rigorous study. Relapse is the
most important treatment outcome. METHODS: Subjects are
509 adolescents discharged from an ASAM-deﬁned Level 1. A
primary inpatient treatment program from 2001–2005. Data
was collected as part of the treatment program’s annual out-
comes evaluation. The sampling frame was all who successfully
completed treatment. Response rate was 61%. Analysis of char-
acteristics of nonrespondents showed no signiﬁcant differences
compared to respondents. The survey is based on a 230-item
questionnaire. Treatment records of each adolescent completing
the questionnaire were obtained for matching treatment 
outcomes from the questionnaire to treatment and sociodemo-
graphic variables contained in treatment records. A comprehen-
sive data set was created from these two sources. Data were
analyzed using Cox proportional hazard regression. RESULTS:
Results indicate race (Whites were 59.2% less likely to relapse
than other races; blacks are 4.9 times more likely.), gender (males
1.28 times more likely), participation in support groups (partic-
ipants 23.7% less likely), school attendance (attendees 21.6%
less likely), supportive friendships (one SD change on scale cor-
responds to a 7.7% reduction in relapse risk), and cannabis
dependence (cannabis diagnosis 28.7% more likely) are signiﬁ-
cant determinants of relapse, certis paribus. CONCLUSIONS:
Several risk factors for relapse are identiﬁed that can be
addressed in primary treatment. For instance, treatment pro-
grams emphasizing friendships skills by application of social cog-
nitive theory might be considered.
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ASSESSMENT OF THE CLINICAL RISK FACTORS FOR
METABOLIC SYNDROME IN A NATIONAL PRIMARY CARE
ELECTRONIC HEALTH RECORD (EHR) DATABASE
Brixner D1, Said Q1, Oderda GM2
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA,
2University of Utah, Salt Lake City, UT, USA
OBJECTIVE: Metabolic syndrome is the constellation of central
obesity, dyslipidemia, impaired glucose tolerance, and elevated
blood pressure (BP). We analyzed the components of metabolic
syndrome via EHR databases. METHODS: Ambulatory elec-
tronic health record data for 3,301,897 patients included demo-
graphics, vitals, labs, drugs and payment types from the GE
Centricity EMR research database. The study period was
January 1, 2003 to December 31, 2004. Patients aged 18 to 64
years with any indicator of cardio-metabolic risk were identiﬁed
by clinical (biometrics), diagnosis (ICD-9 codes) or treatment
(prescriptions) information. RESULTS: The ﬁnal study popula-
tion was 475,651 patients after patients with bariatric surgery
or body mass index (BMI) > 35 kg m2 were excluded. The total
of 266,371 (56%) patients had BP as a risk factor. A total of
162,521 (34.17%) had BMI as a risk factor. When the patients
excluded for morbid obesity were included this rose to 43.8%.
Triglycerides (TG) were identiﬁed as a risk factor in 10.74%,
high density lipoproteins (HDL) in 15.99%, impaired fasting
glucose in 8.83%, diabetes in 7.22% and metabolic syndrome
(diagnosis) in 0.12%. All risk factors, except HDL had values
for all three deﬁnitions (clinical, treatment and diagnosis) of
metabolic syndrome. Of these, out of range BMI values were pri-
marily established by the clinically-based BMI deﬁnition
(33.34%) with the diagnosis and treatment deﬁnitions identify-
ing less that 2%. Over 50% of the patients with elevated BP were
identiﬁed clinically while treatment and diagnosis-based deﬁni-
tions identiﬁed only 18% and 7% of the patients with elevated
BP, respectively. Diabetes was more similar across all three deﬁ-
nitions (range 2.37%–4.69%). CONCLUSION: Distribution of
clinical risk factors in a primary care database closely mirrors
that established by prospective national health surveys. The key
source of identiﬁcation of risk factors is clinically based biomet-
ric information. Studies on metabolic syndrome need to incor-
porate clinically based information.
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COST-EFFECTIVENESS OF TREATING CARDIOMETABOLIC
PATIENTS WITH RIMONABANT (ACOMPLIA®) IN A DANISH
SETTING
Knudsen MS1, Poulsen PB2, Serup-Hansen N3
1Muusmann Research & Consulting AS, Copenhagen, Denmark,
2Muusmann Research & Consulting AS, Kolding, Denmark, 3Sanoﬁ-
aventis, Hoersholm, Denmark
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Cardiometabolic risk factors such as type 2 diabetes or dyslipi-
daemia have become an increasing problem in the developed
countries. Rimonabant 20 mg is a novel treatment in conjunc-
tion with diet and exercise for obese and overweight patients
with associated cardiometabolic risk factors such as type 2 dia-
betes or dyslipidaemia. In the double blinded RCT RIO-Europe
(n = 1508) and RIO-Diabetes (n = 1047), rimonabant was shown
to improve weight, waist circumference, HDL-cholesterol, TG,
HbA1c and other cardiometabolic risk factors in overweight and
obese patients with or without T2DM. The study inclusion cri-
teria correspond to Danish treatment guidelines. OBJECTIVE:
To analyse the cost-effectiveness of rimonabant as a supplement
to diet and exercise in a Danish setting. METHODS: A Markov
model (RAINBOW), evaluating scenarios of 2 and 10 years of
treatment in a Danish setting, was used to evaluate cost-effec-
tiveness based on the RIO-Europe and RIO-Diabetes study.
Modelled outcomes were cost per QALY and LYG. Danish cost
and epidemiological data were applied. RESULTS: Depending on
the treatment length (2 or 10 years) and whether the patients
were obese with or without diabetes, the cost per QALY gained
was between €11,182 and €13,164, while the cost per LYG was
between €13,734 and €39,004. These ratios are within the limits
which are normally considered to be cost-effective. CONCLU-
SIONS: Rimonabant in conjunction with diet and exercise can
be a in overweight or obese patients with dyslipidaemia or type
2 diabetes.
POB3
BURDEN OF ILLNESS OF ABDOMINAL OBESITY:
A RETROSPECTIVE CHART REVIEW
Strens D1, Lamotte M2, Fassotte C3,Annemans L1
1IMS Health, Brussels, Belgium, 2IMS Health, Brussel, Brabant, Belgium,
3sanoﬁ-aventis, Diegem, Brabant, Belgium
OBJECTIVES: Abdominal obesity is a major risk factor for car-
diovascular disease (CVD), diabetes, and related mortality. Little
information is available on the economic burden of abdominal
obesity. Therefore, the objective of this study was to assess the
current medical resource use in patients with abdominal obesity
in Belgium. METHODS: Data on resource utilization was ret-
rospectively (1/8/2004–31/7/2005) collected by general practi-
tioners (GP) in patients aged ≥45 with abdominal obesity and
with either a history of CVD- or diabetes, or either >=2 CVD
risk factors (hypertension, dyslipidemia, impaired glucose toler-
ance). GPs were selected based on setting (urban-rural) and geo-
graphical region (north-south). Cost analysis was performed for
the whole sample, and for 2 subpopulations: patients with a
history of CVD or diabetes (64%) and patients without a CVD-
history or diabetes. Both costs related and not related to obesity
were included. The perspective of the health care payer was
taken. RESULTS: 403 patients were studied. Mean age was 61.2
(St.Err. 0.5), females represented 65.26% of the patients. The
overall cost per year for the entire sample was €1758 (St.Err.
€129) including all costs related and not related to obesity.
Excluding the costs not related to obesity the yearly cost was
€995 (St.Err. €90). For the group of patients with a history of
CVD or diabetes these costs were €2109 (St.Err. €182) and
€1252 (St.Err. €130) respectively. For the subgroup of patients
without a history of CVD nor diabetes these costs were €1099
(St.Err. €138) and €534 (St.Err. €82). CONCLUSIONS: This ret-
rospective chart review shows that patients with abdominal
obesity have a considerable cost, especially in the presence of
CVD or diabetes but also if multiple cardiovascular and/or meta-
bolic risk factors are present. Fifty-seven percent of the total cost
of care is related to the patient’s obesity.
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USING CLAIMS DATA TO UNDERSTAND THE COSTS OF
DIFFERENT HEALTH STATES FOR PATIENTS WITH
CARDIOMETABOLIC RISK
Mangiapane S1, Gothe H1, Schiffhorst G1,Aidelsburger P2,
Fuchs SM2,Wasem J3, Glaeske G4, Häussler B1
1IGES GmbH, Berlin, Germany, 2Carem GmbH, Sauerlach, Germany,
3University of Duisburg-Essen, Essen, Germany, 4ZeS, Centre of Social
Policy Research, Faculty 11: Human and Health Sciences, University of
Bremen, Bremen, Germany
OBJECTIVES: In order to evaluate the costs of different health
states for patients with cardiometabolic risk, a study was per-
formed to operationalize these health states, to identify individ-
uals from a claims database and assign them to the health states.
METHODS: Claims data of a German sickness fund with 1.5
million beneﬁciaries were used for the years 2000 to 2004. Only
patients aged 18–80 years were included who were continuously
covered by the health insurance during this period. Health 
states were composed of different attributes (diabetes mellitus
with/without micro- or macrovascular complication, hyperten-
sion, hypercholesteremia, hypertriglyceridemia, coronary heart
disease, obesity), each of them being transposed into appropri-
ate ATC codes or ICD-10 codes (inpatient, outpatient, sick leave
diagnosis). Patients were selected from the database according to
their health state pattern. RESULTS: Out of n = 774,132 bene-
ﬁciaries (62% male), n = 736,653 (95%) could be assigned to
one of the deﬁned health states. Most of them (58%) were allo-
cated to the health state without any of the deﬁned attributes.
27% had 1 to 4 cardiometabolic risk factors, but no diabetes.
Four percent had no diabetes, but had already experienced car-
diovascular diseases such as myocardial infarction and/or stroke.
6% matched one of the diabetes related health states. CON-
CLUSION: Typical limitations of any analysis performed on the
basis of claims data should be borne in mind. These comprise
lack of diagnostic accuracy and incomplete knowledge of the
patients’ case histories and clinical measures for severity of
illness. Nonetheless, claims data provide useful information for
economic modelling, as they derive from a naturalistic setting
and allow an unbiased view on health care delivery and utiliza-
tion under real-life conditions. This can determine the authen-
ticity of economic models.
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A MODELLED COST-EFFECTIVENESS EVALUATION OF
SIBUTRAMINE THERAPY IN A HIGH RISK OBESE
POPULATION
Walters N1, Makino K1, Hutchinson J1, Shorter N2, Swanson M2,
Schulz M2
1M-TAG, a unit of IMS, Chatswood, NSW, Australia, 2Abbott
Australasia, Botany, NSW, Australia
OBJECTIVES: Obesity is a major risk factor for type 2 diabetes,
cardiovascular disease and stroke. Moderate weight loss of
5–10% is proven to be beneﬁcial, but often difﬁcult to achieve
with diet/exercise alone. The addition of sibutramine can reduce
and maintain weight loss through increased satiety and enhanced
resting metabolic rate. This study reviews the safety, efﬁcacy 
and cost-effectiveness of sibutramine with diet/exercise in obese
patients. METHODS: A patient level analysis was conducted of
23 RCTs of sibutramine with diet/exercise compared with
diet/exercise alone. Dichotomous outcomes (proportion of
patients losing ≥5% body weight) and multivariate risk factor-
adjusted continuous means (BMI, SBP/DBP, HbA1c and lipids)
were calculated. Least squares regression models were developed
to determine the relationship between BMI change and cardio-
